These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4055045)

  • 1. The use of cefotaxime in the treatment of gram-positive pneumonias.
    Jenkinson SG
    Infection; 1985; 13 Suppl 1():S14-7. PubMed ID: 4055045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of cefotaxime therapy in infections caused by gram-positive pathogens.
    Iannini PB
    Infection; 1985; 13 Suppl 1():S3-6. PubMed ID: 4055052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of the effect of cefotaxime in senile pneumonia caused by gram-positive and gram-negative bacteria.
    Katsunuma H
    Infection; 1985; 13 Suppl 1():S18-24. PubMed ID: 4055049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of cefotaxime in gram-positive surgical infections.
    Wittmann DH; Frommelt L
    Infection; 1985; 13 Suppl 1():S37-42. PubMed ID: 4055054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.
    LeFrock J; Mader J; Smith B; Carr B
    Infection; 1985; 13 Suppl 1():S50-5. PubMed ID: 4055056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefotaxime: single agent therapy for infections in cancer patients with adequate granulocyte counts.
    Rolston K; Bolivar R; Fainstein V; Jones P; Elting L; Bodey GP
    J Antimicrob Chemother; 1985 Jan; 15(1):91-6. PubMed ID: 3972760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ceftazidime versus cefotaxime in the therapy of severe infections in intensive care patients].
    Müller E; Heinkelein J
    Infection; 1987; 15 Suppl 4():S173-8. PubMed ID: 3312030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience of cefotaxime in infections caused by gram-positive pathogens.
    Bassetti D; Solbiati M; Fraizzoli G
    Infection; 1985; 13 Suppl 1():S112-4. PubMed ID: 4055040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the use of cefotaxime in the treatment of skin and skin structure infections, with special reference to gram-positive pathogens.
    Karakusis PH; Trenholme GM; Levin S
    Infection; 1985; 13 Suppl 1():S46-9. PubMed ID: 4055055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefotaxime for the treatment of gram-positive urinary tract infection.
    Piccinno A; Pagliarulo A
    Infection; 1985; 13 Suppl 1():S100-2. PubMed ID: 4055038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations.
    Fernández-Guerrero M; Gudiol F; Rodriguez-Torres A; Arnau C; Valdés L; Vallvé C
    Infection; 1991; 19 Suppl 6():S320-5. PubMed ID: 1791077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with cefotaxime in infections caused by gram-positive pathogens, especially Staphylococcus aureus.
    Fujii R
    Infection; 1985; 13 Suppl 1():S9-13. PubMed ID: 4055062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.
    Schleupner CJ
    Infection; 1985; 13 Suppl 1():S28-33. PubMed ID: 4055051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.
    Francke EL; Neu HC
    Am J Med; 1981 Sep; 71(3):435-42. PubMed ID: 6269426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experience of cefotaxime (author's transl)].
    Portier H; Carbon C; Boussougant Y; Destaing F
    Nouv Presse Med; 1981 Feb; 10(8):607-11. PubMed ID: 6259603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftizoxime vs. cefotaxime--a comparative randomized multicenter study.
    Segev S; Kitzes R; Rubinstein E; Pitlik S; Samra Y; Shenkman L; Weinberg M
    Isr J Med Sci; 1988 Aug; 24(8):410-4. PubMed ID: 3045049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefotaxime: efficacy and tolerance in lower respiratory tract infections caused by gram-positive cocci.
    Lode H; Glatzel PD
    Infection; 1985; 13 Suppl 1():S25-7. PubMed ID: 4055050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.
    Helwig HF
    Infection; 1985; 13 Suppl 1():S62-7. PubMed ID: 4055057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of ceftizoxime, cefotaxime and latamoxef in the treatment of bacterial pneumonia in high risk patients.
    Yangco BG; Baird I; Lorber B; Noble R; Bermudez R; Silverblatt F; Vasquez G
    J Antimicrob Chemother; 1987 Feb; 19(2):239-48. PubMed ID: 3553135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.
    Schleupner CJ; Engle JC
    Antimicrob Agents Chemother; 1982 Feb; 21(2):327-33. PubMed ID: 6280600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.